CO5690559A2 - BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATE - Google Patents

BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATE

Info

Publication number
CO5690559A2
CO5690559A2 CO05013218A CO05013218A CO5690559A2 CO 5690559 A2 CO5690559 A2 CO 5690559A2 CO 05013218 A CO05013218 A CO 05013218A CO 05013218 A CO05013218 A CO 05013218A CO 5690559 A2 CO5690559 A2 CO 5690559A2
Authority
CO
Colombia
Prior art keywords
trihydrate
chlorhydrate
drugs containing
bayer healthcare
vardenafil hydrochloride
Prior art date
Application number
CO05013218A
Other languages
Spanish (es)
Inventor
Peter Serno
Alfons Grunenberg
Andreas Ohm
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Priority to CO05013218A priority Critical patent/CO5690559A2/en
Publication of CO5690559A2 publication Critical patent/CO5690559A2/en

Links

Abstract

1.- Procedimiento para la fabricación de medicamentos que contienen clorhidrato de vardenafilo trihidrato en forma sólida, caracterizado porquea) en la preparación del medicamento se utiliza clorhidrato de vardenafilo con un contenido de agua discrecional,b) el clorhidrato de vardenafilo se transforma substancialmente en la forma trihidrato en un intermedio de procesamiento o en el producto final.2.- Procedimiento conforme a la reivindicación 1, caracterizado porque como medicamento se fabrican comprimidos recubiertos.3.- Procedimiento conforme a las reivindicaciones 1 y 2, caracterizado porque el intermedio de procesamiento o el producto final o el comprimido recubierto se pone en contacto con gas humedecido el tiempo necesario para que se forme substancialmente el trihidrato.4.- Procedimiento conforme a la reivindicación 3, caracterizado porque como gas se utiliza aire.1.- Procedure for the manufacture of medicines containing vardenafil hydrochloride trihydrate in solid form, characterized in that a) in the preparation of the drug, vardenafil hydrochloride with a discretionary water content is used, b) vardenafil hydrochloride is substantially transformed into the Trihydrate form in a processing intermediate or in the final product. 2.- Method according to claim 1, characterized in that as a medicament coated tablets are manufactured. 3.- Procedure according to claims 1 and 2, characterized in that the processing intermediate or the final product or the coated tablet is contacted with moistened gas for the time necessary for the trihydrate to form substantially. 4. Method according to claim 3, characterized in that air is used as gas.

CO05013218A 2005-02-14 2005-02-14 BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATE CO5690559A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CO05013218A CO5690559A2 (en) 2005-02-14 2005-02-14 BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CO05013218A CO5690559A2 (en) 2005-02-14 2005-02-14 BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATE

Publications (1)

Publication Number Publication Date
CO5690559A2 true CO5690559A2 (en) 2006-10-31

Family

ID=42138709

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05013218A CO5690559A2 (en) 2005-02-14 2005-02-14 BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATE

Country Status (1)

Country Link
CO (1) CO5690559A2 (en)

Similar Documents

Publication Publication Date Title
TW200806289A (en) Sustained-release formulation of zonisamide
RS52831B (en) Buprenorrphine wafer for drug substitution therapy
PT1957110T (en) Process for manufacturing chewable dosage forms for drug delivery and products thereof
GT200500384A (en) PHARMACEUTICAL DOSAGE METHODS ADMINISTRABLE SOLIDS BY ROUTE WITH MODIFIED RELEASE
AR060019A1 (en) PHARMACEUTICAL COMPOSITION, PRODUCT AND TREATMENT METHOD FOR A COGNITIVE DISORDER AND USES OF AN ACETILCOLINESTERASE INHIBITOR AND A 5- HT6 ANTAGONIST IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A COGNITIVE DISORDER
MX2010005631A (en) Novel cyclic hydrocarbon compounds for the treatment of diseases.
WO2007031887A3 (en) Extended release pharmaceutical composition of metformin and a process for producing it
ATE538777T1 (en) MEDICINAL PRODUCTS CONTAINING VARDENAFIL HYDROCHLORIDE TRIHYDRATE AND THEIR PRODUCTION PROCESS
TNSN08279A1 (en) Bayer healthcare ag
BRPI0610780A2 (en) disintegrating tablet pharmaceutical formulation, and methods for treating a patient in need of olanzapine treatment, and for producing the tablet pharmaceutical formulation
BRPI0520797B8 (en) bilayer compressed pharmaceutical dosage form
IL213671A (en) Pharmaceutical compositions comprising aleglitazar, process for their manufacture and use thereof in the preparation of medicaments
ZA200506992B (en) Fibrate tablet and method for the production thereof
PE20120956A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING BUPRENORPHINE AND NALMEFENE
EP4265298A3 (en) Salt
SG148120A1 (en) An oral pharmaceutical and an oral care product
CO5690559A2 (en) BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATE
EA201270269A1 (en) PHARMACEUTICAL TABLET CONTAINING ROSUVASTATIN CALCIUM
CO6410284A2 (en) ORAL PHARMACEUTICAL COMPOSITION FOR USE IN RESPIRATORY DISEASES
CN102727515A (en) Medicinal preparation for treating dermatophytosis
TH75887A (en)
MX2010006317A (en) Oral pharmaceutical composition with an antihistamine and decongestant.
EE200600045A (en) A medicament for the treatment and prophylaxis of cancer, a pharmaceutical composition, a process for the preparation of a pharmaceutical composition
IN2013MU03389A (en)
ECSP11011279A (en) ORAL PHARMACEUTICAL COMPOSITION FOR USE IN RESPIRATORY DISEASES

Legal Events

Date Code Title Description
FC Application refused